BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 25.11.2016

Bioequivalence Recommendations for Cyclobenzaprine Hydrochloride; Revised Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a revised draft guidance for industry on generic cyclobenzaprine hydrochloride extended release capsules, entitled "Draft Guidance on Cyclobenzaprine Hydrochloride." The recommendations provide specific guidance on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for cyclobenzaprine hydrochloride extended release capsules.

Source: Federal Register — Food and Drug AdministrationOpen original release →